CellSource (TYO:4880) is executing an absorption-type company split involving its subsidiary, Medibase, and GMO Beauty, according to a Tuesday filing.
The split is planned for May 1, subject to shareholder approval on March 21, with GMO Beauty acquiring the Medibase business and related assets for 300 million yen.
CellSource's shares gained more than 2% recently.
Price (JPY): $835.00, Change: $+21, Percent Change: +2.58%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.